Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH

Video

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

Jeffrey Wolf, MD, of the University of California San Francisco, discussed with CancerNetwork the implications of the results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma presented at the 2020 American Society of Hematology (ASH) Annual Meeting.

Transcription:

So, what we discovered when we looked at those 58 people who had decisions made, and we compared it to the other patients where decisions weren’t made, we found that there were more people that achieved MRD-zero because the change allowed them to get to MRD-zero. And, for patients [where] their decision was controlled longer, that is the progression-free survival, improved significantly from 75 months to 97 months. So, we believe that by measuring MRD and using it to make decisions, you can achieve better outcomes for your patient.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Related Content